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ABSTRACT
Background: A recent meta-analysis showed that
intravenous and nebulised magnesium sulphate have similar
levels of evidence to support their use in the treatment of
acute asthma in adults. This consisted of weak evidence of
effect on respiratory function and hospital admissions, with
wide confidence intervals ranging from no effect to
significant positive effects. Current BTS/SIGN guidelines
suggest an equivocal role for intravenous magnesium
sulphate and no role for nebulised magnesium sulphate. A
study was performed to assess what emergency physicians
currently do in their management of acute asthma.
Method: A postal survey was undertaken of all adult
emergency departments within the UK. A structured question
naire was sent to all clinical leads in emergency medicine
about their current usage of both intravenous and nebulised
magnesium sulphate in the treatment of acute asthma.
Results: 180 of the 251 emergency departments in the
UK responded (72%). Magnesium sulphate was used in
93%, mostly because it was expected to relieve
breathlessness (70%) or reduce HDU/ITU admissions
(51%). It was predominantly given to those patients with
acute severe asthma (84%) and life-threatening exacer-
bations (87%), with most stating they would give the drug
if there was no response to repeated nebulisers (68%). In
comparison, nebulised magnesium sulphate was only
used in two emergency departments (1%). The main
reason for not administering the drug via a nebuliser was
insufficient evidence (51%).
Conclusions: Intravenous magnesium sulphate is widely
used for acute asthma, usually for patients with severe or
life-threatening asthma who have not responded to initial
treatment. Nebulised magnesium sulphate, by contrast, is
hardly used at all. The use of intravenous magnesium
sulphate is more extensive than current guidelines or
available evidence would appear to support.
Asthma is estimated to affect one in 12 adults in
the UK.1 This equates to 4.1 million of the adult
population. It is also estimated that, following an
acute exacerbation of asthma, 75% of the sub-
sequent hospital admissions are avoidable.1
A recent meta-analysis of the use of intravenous
and nebulised magnesium sulphate reviewed 24
relevant studies consisting of 1669 patients. They
showed that both methods of delivering magne-
sium sulphate have similar levels of evidence to
support their use in the treatment of acute asthma
in adults.2 However, the evidence relating to the
effect on respiratory function and hospital admis-
sions was shown to be weak, with wide confidence
intervals ranging from no effect to significant
positive effects. Meanwhile, the current BTS/
SIGN guidelines suggest that intravenous magne-
sium sulphate should be considered in the manage-
ment of acute severe and life-threatening asthma if
there is no response to initial therapy, but they do
not mention nebulised magnesium sulphate.3
We wanted to assess how emergency physicians
currently use magnesium sulphate in their manage-
ment of acute asthma.
METHODS
A postal survey was undertaken of all adult
emergency departments within the UK. A struc-
tured questionnaire was sent to all clinical leads in
emergency medicine about their current usage of
both intravenous and nebulised magnesium sul-
phate in the treatment of acute asthma.
The questionnaire was developed by the authors.
A 10-question model was piloted and reviewed
using a small cohort of local senior emergency
doctors. The questionnaire was modified to
improve response by virtue of saliency and visual
appeal (see Appendix 1).
The survey was sent out to all clinical leads with
a covering letter from the authors and a stamped
addressed envelope for ease of return. All 251
emergency departments in the UK that cater to the
adult population were contacted. Non-responders
were sent up to two re-mailings 3 weeks apart.
RESULTS
After three mail shots a response rate of 72% (180/
251) was achieved. The responses indicated that
93% of departments (n = 167) currently use
intravenous magnesium sulphate in their treat-
ment of acute exacerbations of asthma, while only
two (1%) use nebulised magnesium sulphate, of
which one reported a ‘‘single episode last month in
the presence of an ITU consultant’’ and the other
reported that ‘‘my junior staff do at least’’.
Table 1 shows the reasons given for using
magnesium sulphate in acute asthma. Most
respondents used intravenous magnesium sulphate
to improve breathlessness, about one-half to avoid
HDU/ITU admission and one-third to improve
survival. Only 3% used magnesium sulphate to
facilitate patient discharge home.
In terms of the management protocol for acute
asthma, our respondents believed that the drug
should primarily be administered to those who had
had no response to repeated nebulisers (68%) (table 2).
Table 3 shows the type of patients that respon-
dents identified as being appropriate for treatment
with magnesium sulphate. In current practice the
cohort who use intravenous magnesium administer
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the drug if the exacerbation is classified as acute severe or if there
are life threatening features (84% and 87% respectively).
Table 4 shows the reasons for not administering magnesium
sulphate, so responses mainly relate to nebulised treatment. About
half of the respondents believed that there is insufficient research
available to justify using nebulised magnesium sulphate and half
gave other reasons. The main other reasons were ‘‘unaware of its
use’’ (37%), ‘‘prefer using intravenous’’ (14%) and ‘‘no personal
experience’’ (13%). A combined 24% stated that nebulised
magnesium sulphate was not within their guidelines; that included
BTS-defined (8%), within their department (10%) or dictated to
them by their in-house respiratory physician colleagues (6%).
DISCUSSION
The results from our survey showed that 93% of adult emergency
departments are currently using intravenous magnesium sul-
phate, principally to relieve breathlessness or avoid HDU/ITU
admission in patients with severe or life-threatening asthma who
do not respond to initial treatment. At present, nebulised
magnesium sulphate does not appear to be used in the manage-
ment of acute asthma, with most emergency practitioners feeling
that there was insufficient evidence to justify its use.
With over 90% use of intravenous magnesium sulphate in the
treatment of acute asthma, our results appear to show an
established practice within UK emergency departments consis-
tent with current BTS/SIGN guidelines. However, there is still
uncertainty about when it should be given and the rationale for its
use. This is perhaps unsurprising as the guidelines only state that
its role should be ‘‘considered’’ in severe or life-threatening asthma
that has not responded to initial treatment. Despite this rather
equivocal recommendation, some respondents indicated that they
used it earlier and in less severe cases than the guidelines suggest.
The equivocal role of intravenous magnesium sulphate in the
guidelines reflects the lack of strong evidence to support its use in
acute asthma. In addition to a recent meta-analysis, there have
been previous reviews looking at the efficacy of the drug in both
the intravenous and nebulised formats. None of these reviews
produced strong evidence to show improvement in symptoms or
reduced hospital admission.4–9 There was some evidence of
improvement in respiratory function, but it is not clear how this
relates to patient well-being or clinical decision-making.
Although the most recent meta-analysis2 is comprehensive in
its inclusion of all the current evidence, it does not provide clear
guidance. The analysis concludes that there is only weak
evidence available at present to advocate the use of intravenous
or nebulised magnesium sulphate. As a result, a large multi-
centre trial of intravenous and nebulised magnesium sulphate
(the 3 mg trial) is currently underway to clarify the role of
magnesium sulphate in adults with acute severe asthma.10
Our study has some limitations. The response rate was over
70%, which is acceptable11 but may still result in some non-
response bias. It is not clear how non-responders might differ
from responders in this survey, but we might expect them to
have less certainty about the role of magnesium sulphate in
acute asthma or less interest in the topic. Another inevitable
limitation of this method is that we can only ascertain what
respondents tell us happens in their departments, not actually
what does happen. However, magnesium sulphate is a relatively
simple intervention, so there is no reason to suspect that
reported use would differ dramatically from actual use.
In conclusion, we found that intravenous magnesium sulphate
is used in the treatment of acute asthma in over 90% of emergency
departments, usually for patients with severe or life-threatening
asthma who have not responded to initial treatment. Nebulised
magnesium sulphate, by contrast, is hardly used at all. The use of
intravenous magnesium sulphate appears to be more extensive
than current guidelines or available evidence support.
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EMQs: Paediatrics
QUESTION 1
The following statements are true regarding umbilical pathology:
a. Umbilical erythema in a neonate may suggest omphalitis
and require a full septic evaluation.
b. Umbilical erythema in an older infant can be a sign of cow's
milk protein allergy.
c. Regular umbilical cord antiseptic wipes in neonates have
been proven to reduce the incidence of omphalitis compared
to simply keeping the cord dry and clean.
d. Umbilical erythema in a neonate with a clear, light-yellow
fluid discharge the consistency of water from the umbilicus
should raise the suspicion of bladder outlet obstruction.
QUESTION 2
The following statements are true regarding children with
gastroenteritis:
a. Dilution of coca-cola with two parts distilled water reduces
its osmolarity to approximate that of many accepted oral
rehydration fluids and is therefore a viable and more easily
administered alternative.
b. A single oral dose of ondansetron improves the success of oral
rehydration in dehydrated children with gastroenteritis,
resulting in a reduction of more than 50% in both the
proportion of children who vomit during oral rehydration and
the proportion treated with IV fluids
c. The standard oral dose of ondansetron for children with
severe vomiting due to gastroenteritis is 4 mg.
d. Ondansetron may cause increased diarrhoea in children
with gastroenteritis.
QUESTION 3
The following statements are true regarding syncope in children:
a. Up to 20% of children will suffer a syncopal episode by
adolescence.
b. All children presenting to the ED after a syncopal episode
should undergo a head CT.
c. Loss of consciousness in association with exercise or stress is
commonly due to epilepsy.
d. It is important to document the family history in a patient
with syncope.
See page 830 for answers
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